PW Medtech Group Ltd (1358) Fair Value & Analysis
Healthcare · HK · Market cap HK$1.6B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated 3 days ago
Share price −15.4% over the past month.
A solid business, screening 122% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$1.26). The market is more pessimistic than our downside scenario.
- Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.3855 – HK$1.56 · fair‑value band HK$1.26 – HK$2.11 · the HK$0.9050 price screens below the HK$2.01 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
PW Medtech Group Ltd (1358) currently trades at HK$0.9050, while our model-based Fair Value estimate is HK$2.01, implying the stock looks roughly 122.1% undervalued today. The Quality Score stands at 66/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, PW Medtech Group Ltd generated revenue of HK$824M at a net margin of 11.5%. Revenue declined 5.0% year over year. It earns a return on equity of 2.8%. The balance sheet holds a net cash position of HK$1.8B. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$1.26 (bear case) to HK$2.11 (bull case); at HK$0.9050, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -46% fair-value upside, at 122%, 1358 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (HK$2.92) versus Earnings-Based (HK$0.8400). Highest evidence: Growth DCF (80).
Notify me when 1358 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 67 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PW Medtech Group Limited, an investment holding company, operates as a medical device company in China, India, the Americas, Africa, the rest of Asia, and internationally. It operates in three segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business.
Full company description
PW Medtech Group Limited, an investment holding company, operates as a medical device company in China, India, the Americas, Africa, the rest of Asia, and internationally. It operates in three segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business. The company offers advanced infusion sets, such as non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, and insulin needles and pens; hemodialysis and blood purification medical devices; and high-flux hemodialyzers, low-flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. It also provides animal-derived regenerative medical biomaterials and human tissue repair alternative products. The company was formerly known as Pyholding Limited and changed its name to PW Medtech Group Limited in June 2013. PW Medtech Group Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PW Medtech Group Ltd reported revenue of HK$824M in FY2025 versus HK$271M in FY2021, a compound +32.0%/yr. Reported net income was HK$94.4M in FY2025, compounding −40.2%/yr from FY2021.
of which total revenue +5.1 pp · buybacks/dilution +1.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 1358: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 202 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $401.27 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €164.40 | €68.55 | -58% |
| Medline Inc MDLN | $35.50 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $181.41 | $100.46 | -45% |
| Alcon Inc ALC | $73.58 | $39.78 | -46% |
| ResMed Inc RMD | $226.00 | $187.89 | -17% |
| West Pharmaceutical Services, Inc WST | $352.29 | $141.58 | -60% |
| Sartorius Stedim Biotech S.A DIM | €180.30 | €48.88 | -73% |
| Coloplast A/S COLOB | kr 429.70 | kr 382.22 | -11% |
| Gan & Lee Pharmaceuticals., a biopharmaceutical company, 603087 | ¥77.48 | ¥27.22 | -65% |
Compare PW Medtech Group Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PW Medtech Group Ltd (1358) overvalued or undervalued?
What is the fair value of 1358?
What is the quality score of 1358?
What is the revenue of PW Medtech Group Ltd (1358)?
What is the net profit margin of 1358?
Does PW Medtech Group Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PW Medtech Group Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.